In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
Among other benefits, addition of Loxo will broaden scope of Lilly’s oncology portfolio into precision medicines
Nanobiotix and MD Anderson Cancer Center collaborate on new product
PAN Cancer trial launches to evaluate Owlstone Medical’s Breath Biopsy platform for cancer diagnosis
ArcherDX Inc. has received a Breakthrough Device designation for its companion diagnostic assay
New liquid biopsy technique a powerful diagnostic tool for early detection of ovarian, endometrial cancer
AbbVie's partnership with TeneoBio brings it into the effort to develop BCMA-targeting immunotherapeutics against multiple myeloma
University of Cambridge team explores the role that ATM mutations play in a rare neurodegenerative disease and in cancer drug sensitivity
Company provides update on Phase 3 clinical trial of ibutinib in combo with chemo agents

Columbia Business School report examines how cancer drugs have impacted mortality for patients
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.